Identifcation of a DNA methylome signature of esophageal squamous cell carcinoma and potential epigenetic biomarkers

Epigenetics

Volumn 6, Issue 10, 2011, Pages 1217-1227

  Lima, Sheila C S ^a,b   Hernandez Vargas, Hector ^a   Simão, Tatiana ^b,c   Durand, Geoffroy ^a   Kruel, Cleber Dario Pinto ^d   le Clvez Kelm, Florence ^a   Pinto, Felipe Ribeiro Luis ^b,c   Herceg, Zdenko ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^c STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^d HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Cancer biomarkers; DNA methylation; Epigenomics; Esophageal squamous cell carcinoma (ESCC)

Indexed keywords

BIOLOGICAL MARKER; DNA; INTERLEUKIN 10; PROTEIN; TREFOIL FACTOR 1; UNCLASSIFIED DRUG; TFF1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SUSCEPTIBILITY; CELL COMMUNICATION; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DNA MICROARRAY; EARLY DIAGNOSIS; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS MUCOSA; FEMALE; HUMAN; HUMAN TISSUE; MALE; PROMOTER REGION; PYROSEQUENCING; SIGNAL TRANSDUCTION; TUMOR GENE; CHEMISTRY; DNA SEQUENCE; ESOPHAGUS TUMOR; GENETIC EPIGENESIS; GENETIC MARKER; GENETICS; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; ESOPHAGEAL NEOPLASMS; GENETIC MARKERS; HUMANS; PROMOTER REGIONS, GENETIC; SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEINS;

EID: 80053455840     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.6.10.17199     Document Type: Article

References (57)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127:2893-917; PMID:21351269; DOI:10.1002/ ijc.25516.
2. Vizcaino AP, Moreno V, Lambert R, Parkin DM. Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer 2002; 99:860-8; PMID:12115489; DOI:10.1002/ijc.10427.
3. Allen JW, Richardson JD, Edwards MJ. Squamous cell carcinoma of the esophagus: a review and update. Surg Oncol 1997; 6:193-200; PMID:9775405; DOI:10.1016/S0960-7404(98)00003-6.
4. Dawsey SM, Lewin KJ, Wang GQ, Liu FS, Nieberg RK, Yu Y, et al. Squamous esophageal histology and subsequent risk of squamous cell carcinoma of the esophagus. A prospective follow-up study from Linxian, China. Cancer 1994; 74:1686-92; PMID:8082069; DOI:10.1002/1097-0142(19940915)74:6<1686::AID-CNCR2820740608>3.0.CO;2-V.
5. Toh Y, Oki E, Ohgaki K, Sakamoto Y, Ito S, Egashira A, et al. Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: molecular mechanisms of carcinogenesis. Int J Clin Oncol 2010; 15:135-44; PMID:20224883; DOI:10.1007/s10147-010-0057-6.
6. Rossini A, Rapozo DC, Soares Lima SC, Guimaraes DP, Ferreira MA, Teixeira R, et al. Polymorphisms of GSTP1 and GSTT1, but not of CYP2A6, CYP2E1 or GSTM1, modify the risk for esophageal cancer in a western population. Carcinogenesis 2007; 28:2537-42; PMID:17916905; DOI:10.1093/carcin/bgm222.
7. Islami F, Boffetta P, Ren JS, Pedoeim L, Khatib D, Kamangar F High-temperature beverages and foods and esophageal cancer risk-a systematic review. Int J Cancer 2009; 125:491-524; PMID:19415743; DOI:10.1002/ijc.24445.
8. Rossini A, de Almeida Simao T, Marques CB, Soares-Lima SC, Herbster S, Rapozo DC, et al. Tp53 mutation profile of esophageal squamous cell carcinomas of patients from Southeastern Brazil. Mutat Res 2010; 696:10-5; PMID:19944185.
9. Shamma A, Doki Y, Shiozaki H, Tsujinaka T, Yamamoto M, Inoue M, et al. Cyclin D1 overexpres-sion in esophageal dysplasia: a possible biomarker for carcinogenesis of esophageal squamous cell carcinoma. Int J Oncol 2000; 16:261-6; PMID:10639568.
10. Zhang G, Zhang Q, Zhang Q, Yin L, Li S, Cheng K, et al. Expression of nucleostemin, epidermal growth factor and epidermal growth factor receptor in human esophageal squamous cell carcinoma tissues. J Cancer Res Clin Oncol 2010; 136:587-94; PMID:19823871; DOI:10.1007/s00432-009-0693-2.
11. Iacobuzio-Donahue CA. Epigenetic changes in cancer. Annu Rev Pathol 2009; 4:229-49; PMID:18840073; DOI:10.1146/annurev.pathol.3.121806.151442.
12. Herceg Z. Epigenetics and cancer: towards an evaluation of the impact of environmental and dietary factors. Mutagenesis 2007; 22:91-103; PMID:17284773; DOI:10.1093/mutage/gel068.
13. Lima SCS, Hernandez-Vargas H, Herceg Z. Epigenetic signatures in cancer: Implications for the control of cancer in the clinic. Curr Opin Mol Ther 2010; 12:316-24; PMID:20521220.
14. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128:683-92; PMID:17320506; DOI:10.1016/j. cell.2007.01.029.
15. Wang J, Sasco AJ, Fu C, Xue H, Guo G, Hua Z, et al. Aberrant DNA methylation of P16, MGMT and hMLH1 genes in combination with MTHFR C677T genetic polymorphism in esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2008; 17:118-25; PMID:18199718; DOI:10.1158/1055-9965.EPI-07-0733.
16. Kim YT, Park JY, Jeon YK, Park SJ, Song JY, Kang CH, et al. Aberrant promoter CpG island hypermethylation of the adenomatosis polyposis coli gene can serve as a good prognostic factor by affecting lymph node metastasis in squamous cell carcinoma of the esophagus. Dis Esophagus 2009; 22:143-50; PMID:18847451; DOI:10.1111/j.1442-2050.2008.00862.x.
17. Guo M, Ren J, House MG, Qi Y, Brock MV, Herman JG. Accumulation of promoter methylation suggests epigenetic progression in squamous cell carcinoma of the esophagus. Clin Cancer Res 2006; 12:4515-22; PMID:16899597; DOI:10.1158/1078-0432.CCR-05-2858.
18. Wong ML, Tao Q, Fu L, Wong KY, Qiu GH, Law FBF, et al. Aberrant promoter hypermethylation and silencing of the critical 3p21 tumour suppressor gene, RASSF1A, in Chinese oesophageal squamous cell carcinoma. Int J Oncol 2006; 28:767-73; PMID:16465383.
19. Soutto M, Peng D, Razvi M, Ruemmele P, Hartmann A, Roessner A, et al. Epigenetic and genetic silencing of CHFR in esophageal adenocarcinomas. Cancer 2010; 116:4033-42; PMID:20564104; DOI:10.1002/ cncr.25151.
20. Guo M, House MG, Suzuki H, Ye Y, Brock MV, Lu F, et al. Epigenetic silencing of CDX2 is a feature of squamous esophageal cancer. Int J Cancer 2007; 121:1219-26; PMID:17534889; DOI:10.1002/ijc.22828.
21. Yamashita K, Upadhyay S, Osada M, Hoque MO, Xiao Y, Mori M, et al. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2002; 2:485-95; PMID:12498717; DOI:10.1016/ S1535-6108(02)00215-5.
22. Kim MS, Yamashita K, Baek JH, Park HL, Carvalho AL, Osada M, et al. N-methyl-D-aspartate receptor type 2B is epigenetically inactivated and exhibits tumor-suppressive activity in human esophageal cancer. Cancer Res 2006; 66:3409-18; PMID:16585162; DOI:10.1158/0008-5472.CAN-05-1608.
23. Arai M, Imazeki F, Sakai Y, Mikata R, Tada M, Seki N, et al. Analysis of the methylation status of genes upregulated by the demethylating agent, 5-aza-2'-de-oxycytidine, in esophageal squamous cell carcinoma. Oncol Rep 2008; 20:405-12; PMID:18636205.
24. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3:415-28; PMID:12042769.
25. Zhang S, Wei L, Zhang A, Zhang L, Yu H. RUNX3 gene methylation in epithelial ovarian cancer tissues and ovarian cancer cell lines. OMICS 2009; 13:307-11; PMID:19645591; DOI:10.1089/omi.2009.0030.
26. Ramírez N, Bandres E, Navarro A, Pons A, Jansa S, Moreno I, et al. Epigenetic events in normal colonic mucosa surrounding colorectal cancer lesions. Eur J Cancer 2008; 44:2689-95; PMID:18938072; DOI:10.1016/j.ejca.2008.09.004.
27. Oka D, Yamashita S, Tomioka T, Nakanishi Y, Kato H, Kaminishi M, et al. The presence of aberrant DNA methylation in noncancerous esophageal mucosae in association with smoking history: a target for risk diagnosis and prevention of esophageal cancers. Cancer 2009; 115:3412-26; PMID:19472401; DOI:10.1002/ cncr.24394.
28. Ribieras S, Tomasetto C, Rio MC. The pS2/TFF1 trefoil factor, from basic research to clinical applications. Biochim Biophys Acta 1998; 1378:61-77; PMID:9739760.
29. Nie Y, Liao J, Zhao X, Song Y, Yang Gy, Wang LD, et al. Detection of multiple gene hypermethylation in the development of esophageal squamous cell carcinoma. Carcinogenesis 2002; 23:1713-20; PMID:12376481; DOI:10.1093/carcin/23.10.1713.
30. Yamaguchi S, Kato H, Miyazaki T, Sohda M, Kimura H, Ide M, et al. RASSF1A gene promoter methylation in esophageal cancer specimens. Dis Esophagus 2005; 18:253-6; PMID:16128782; DOI:10.1111/j.1442-2050.2005.00501.x.
31. Saadi A, Shannon NB, Lao-Sirieix P, O'Donovan M, Walker E, Clemons NJ, et al. Stromal genes discriminate preinvasive from invasive disease, predict outcome and highlight inflammatory pathways in digestive cancers. Proc Natl Acad Sci USA 2010; 107:2177-82; PMID:20080664; DOI:10.1073/pnas.0909797107.
32. Gonda TA, Tu S, Wang TC. Chronic inflammation, the tumor microenvironment and carcinogenesis. Cell Cycle 2009; 8:2005-13; PMID:19550141; DOI:10.4161/cc.8.13.8985.
33. Abdel-Latif MM, Duggan S, Reynolds JV, Kelleher D. Inflammation and esophageal carcinogenesis. Curr Opin Pharmacol 2009; 9:396-404; PMID:19596608; DOI:10.1016/j.coph.2009.06.010.
34. Jeanes A, Gottardi CJ, Yap AS. Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene 2008; 27:6920-9; PMID:19029934; DOI:10.1038/onc.2008.343.
35. Chidgey M, Dawson C. Desmosomes: a role in cancer? Br J Cancer 2007; 96:1783-7; PMID:17519903; DOI:10.1038/sj.bjc.6603808.
36. Kerr LD, Duckett CS, Wamsley P, Zhang Q, Chiao P, Nabel G, et al. The proto-oncogene bcl-3 encodes an I kappa B protein. Genes Dev 1992; 6:2352-63; PMID:1459457; DOI:10.1101/gad.6.12a.2352.
37. Canoz O, Rassidakis GZ, Admirand JH, Medeiros LJ. Immunohistochemical detection of BCL-3 in lymphoid neoplasms: a survey of 353 cases. Mod Pathol 2004; 17:911-7; PMID:15105810; DOI:10.1038/ modpathol.3800140.
38. Cogswell PC, Guttridge DC, Funkhouser WK, Baldwin AS. Selective activation of NFkappaB subunits in human breast cancer: potential roles for NFkappaB2/ p52 and for Bcl-3. Oncogene 2000; 19:1123-31; PMID:10713699; DOI:10.1038/sj.onc.1203412.
39. Thornburg NJ, Pathmanathan R, Raab-Traub N. Activation of nuclear factor-kappaB p50 homodimer/ Bcl-3 complexes in nasopharyngeal carcinoma. Cancer Res 2003; 63:8293-301; PMID:14678988.
40. O'Neil BH, Buzkova P, Farrah H, Kashatus D, Sanoff H, Goldberg RM, et al. Expression of nuclear factor-kappaB family proteins in hepatocellular carcinomas. Oncology 2007; 72:97-104; PMID:18025803; DOI:10.1159/000111116.
41. Dietrich D, Lesche R, Tetzner R, Krispin M, Dietrich J, Haedicke W, et al. Analysis of DNA methylation of multiple genes in microdissected cells from formalin-fixed and paraffin-embedded tissues. J Histochem Cytochem 2009; 57:477-89; PMID:19153192; DOI:10.1369/jhc.2009.953026.
42. Henry JA, Bennett MK, Piggott NH, Levett DL, May FE, Westley BR. Expression of the pNR-2/pS2 protein in diverse human epithelial tumours. Br J Cancer 1991; 64:677-82; PMID:1911216; DOI:10.1038/ bjc.1991.380.
43. Welter C, Theisinger B, Seitz G, Tomasetto C, Rio MC, Chambon P, et al. Association of the human spasmolytic polypeptide and an estrogen-induced breast cancer protein (pS2) with human pancreatic carcinoma. Lab Invest 1992; 66:187-92; PMID:1735955.
44. Yang Y, Chisholm GD, Habib FK. The distribution of PSA, cathepsin-D and pS2 in BPH and cancer of the prostate. Prostate 1992; 21:201-8; PMID:1279646; DOI:10.1002/pros.2990210304.
45. Tomasetto C, Wolf C, Rio MC, Mehtali M, LeMeur M, Gerlinger P, et al. Breast cancer protein PS2 synthesis in mammary gland of transgenic mice and secretion into milk. Mol Endocrinol 1989; 3:1579-84; PMID:2481815; DOI:10.1210/mend-3-10-1579.
46. Carvalho R, Kayademir T, Soares P, Canedo P, Sousa S, Oliveira C, et al. Loss of heterozygosity and promoter methylation, but not mutation, may underlie loss of TFF1 in gastric carcinoma. Lab Invest 2002; 82:1319-26; PMID:12379766.
47. Karam SM, Tomasetto C, Rio MC. Amplification and invasiveness of epithelial progenitors during gastric carcinogenesis in trefoil factor 1 knockout mice. Cell Prolif 2008; 41:923-35; PMID:19040570; DOI:10.1111/j.1365-2184.2008.00562.x.
48. Sabo E, Meitner PA, Tavares R, Corless CL, Lauwers GY, Moss SF, et al. Expression analysis of Barretts esophagus-associated high-grade dysplasia in laser capture microdissected archival tissue. Clin Cancer Res 2008; 14:6440-8; PMID:18927283; DOI:10.1158/1078-0432.CCR-08-0302.
49. Fox CA, Sapinoso LM, Zhang H, Zhang W, McLeod HL, Petroni GR, et al. Altered expression of TFF-1 and CES-2 in Barretts Esophagus and associated adenocarcinomas. Neoplasia 2005; 7:407-16; PMID:15967118; DOI:10.1593/neo.04715.
50. Mitas M, Almeida JS, Mikhitarian K, Gillanders WE, Lewin DN, Spyropoulos DD, et al. Accurate discrimination of Barretts esophagus and esophageal adenocarcinoma using a quantitative three-tiered algorithm and multimarker real-time reverse transcription-PCR. Clin Cancer Res 2005; 11:2205-14; PMID:15788668; DOI:10.1158/1078-0432.CCR-04-1091.
51. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16:1215; PMID:3344216; DOI:10.1093/nar/16.3.1215.
52. Hernandez-Vargas H, Lambert MP, Le Calvez-Kelm F, Gouysse G, McKay-Chopin S, Tavtigian SV, et al. Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors. PLoS ONE 2010; 5:9749; PMID:20305825; DOI:10.1371/journal.pone.0009749.
53. ibikova M, Lin Z, Zhou L, Chudin E, Garcia EW, Wu B, et al. High-throughput DNA methylation profiling using universal bead arrays. Genome Res 2006; 16:383-9; PMID:16449502; DOI:10.1101/gr.4410706.
54. Vaissière T, Cuenin C, Paliwal A, Vineis P, Hoek G, Krzyzanowski M, et al. Quantitative analysis of DNA methylation after whole bisulfitome amplification of a minute amount of DNA from body fluids. Epigenetics 2009; 4:221-30; PMID:19458486.
55. Daskalos A, Nikolaidis G, Xinarianos G, Savvari P, Cassidy A, Zakopoulou R, et al. Hypomethylation of retrotransposable elements correlates with genomic instability in non-small cell lung cancer. Int J Cancer 2009; 124:81-7; PMID:18823011; DOI:10.1002/ ijc.23849.
56. Korn EL, Li MC, McShane LM, Simon R. An investigation of two multivariate permutation methods for controlling the false discovery proportion. Stat Med 2007; 26:4428-40; PMID:17357994; DOI:10.1002/ sim.2865.
57. Wright GW, Simon RM. A random variance model for detection of differential gene expression in small micro-array experiments. Bioinformatics 2003; 19:2448-55; PMID: 14668230; DOI:10.1093/bioinformatics/ btg345.